Which stock wins in a battle between these two big biotechs?
News & Analysis: Biogen
Which stock wins in a match-up between these two biotechs?
The biotech had $4.3 billion in sales at risk.
Cutting expenses and repurchasing shares will only get the drugmaker so far.
BIIB earnings call for the period ending June 30, 2019.
Biogen's swing and miss in Alzheimer's disease has weighed on its shares this year.
These three biotech stocks should be outstanding long-term growth vehicles.
Here's how these biotech stocks became the biggest on the market -- and how their future prospects look.
Pfizer could be only the first of several to spend billions buying smaller biotech.
Which of these elite biotechs is the better buy right now?